Characteristics of the patients according to the therapy group.

<p>Characteristics of the patients according to the therapy group.</p

Univariate analysis of the 57 patients with primary esophageal carcinoma containing ≥50%SRCs.

<p>Univariate analysis of the 57 patients with primary esophageal carcinoma containing ≥50%SRCs.</p

Kaplan-Meier survival curves by the presence of SRCs.

<p>Kaplan-Meier survival curves by the presence of SRCs.</p

Hematoxylin and eosin—Stained section (200 magnification) of a biopsy specimen showing (A) SRC≥50% and (B) SRC<50%, and (C) poorly differentiated adenocarcinoma (reference group).

<p>Hematoxylin and eosin—Stained section (200 magnification) of a biopsy specimen showing (A) SRC≥50% and (B) SRC<50%, and (C) poorly differentiated adenocarcinoma (reference group).</p

Perioperative and histopathological variables of the resected specimen.

<p>Perioperative and histopathological variables of the resected specimen.</p

Consort diagram.

<p>Consort diagram.</p

ORs of different outcomes in relation to number of medications.

<p>ADR, Adverse Drug Reactions; CI,Confidence interval; OR, odds ratio. ORs are for risk with increasing of medications by one.</p><p>*Adjusted for age, type of medications and comorbidities.</p><p>ORs of different outcomes in relation to number of medications.</p

Changes (%) in functional ability (IADL test) and cognitive capacity (MMSE test) among survivors from 2009 to 2014.

<p>NP, Non-polypharmacy; P, Polypharmacy; EP, Excessive Polypharmacy; ADR, Adverse Drug Reactions. p-Values for categorical variables were measured with a chi-square (x²) test and for continuous variables with ANOVA.</p><p>Changes (%) in functional ability (IADL test) and cognitive capacity (MMSE test) among survivors from 2009 to 2014.</p

Baseline characteristics of the study population (n = 1562).

<p>Baseline characteristics of the study population (n = 1562).</p